Find Zavegepant HCl manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Vazegepant, Bms-742413, Bhv-3500, Zavegepant [usan], Odu3zaz94j, Bms-742413-01
Molecular Formula
C36H46N8O3
Molecular Weight
638.8  g/mol
InChI Key
JJVAPHYEOZSKJZ-JGCGQSQUSA-N
FDA UNII
ODU3ZAZ94J

Zavegepant HCl
Zavegepant is a highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, with potential analgesic and immunomodulating activities. Upon administration, zavegepant targets, binds to and inhibits the activity of CGRP receptors located on mast cells in the brain. This may inhibit neurogenic inflammation caused by trigeminal nerve release of CGRP. In addition, by blocking the CGRP receptors located in smooth muscle cells within vessel walls, zavegepant inhibits the pathologic dilation of intracranial arteries. Zavegepant, by blocking the CGRP receptors, also suppresses the transmission of pain by inhibiting the central relay of pain signals from the trigeminal nerve to the caudal trigeminal nucleus. Altogether, this may relieve migraine. As CGRP receptors induce the release of pro-inflammatory mediators, such as interleukin-6 (IL-6), from inflammatory cells, zavegepant may prevent an IL-6-mediated inflammatory response. Zavegepant may also inhibit the CGRP-mediated induction of eosinophil migration and the stimulation of beta-integrin-mediated T cell adhesion to fibronectin at the site of inflammation, and may abrogate the CGRP-mediated polarization of the T cell response towards the pro-inflammatory state characterized by Th17 and IL-17. This may improve lung inflammation and oxygenation, prevent edema, and further lung injury. CGRP, a 37 amino-acid peptide expressed in and released from a subset of polymodal primary sensory neurons of the trigeminal ganglion and nerve fibers projecting to the airways and by pulmonary neuroendocrine cells, plays an important role in pain transmission, inflammation, and neurogenic vasodilatation. It is released upon acute lung injury and upregulation of transient receptor potential (TRP) channels.
1 2D Structure

Zavegepant HCl

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide
2.1.2 InChI
InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
2.1.3 InChI Key
JJVAPHYEOZSKJZ-JGCGQSQUSA-N
2.1.4 Canonical SMILES
CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
2.1.5 Isomeric SMILES
CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
2.2 Other Identifiers
2.2.1 UNII
ODU3ZAZ94J
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 742413

2. Bms-742413

3. N-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl))-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide

2.3.2 Depositor-Supplied Synonyms

1. Vazegepant

2. Bms-742413

3. Bhv-3500

4. Zavegepant [usan]

5. Odu3zaz94j

6. Bms-742413-01

7. 1337918-83-8

8. Chembl2397415

9. N-[(2r)-3-(7-methyl-1h-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1h-quinolin-3-yl)piperidine-1-carboxamide

10. 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-

11. 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-1-piperidinecarboxamide

12. Zavegepant [inn]

13. Unii-odu3zaz94j

14. Vazegepant [who-dd]

15. Schembl107428

16. Gtpl11513

17. Ex-a6698

18. Bdbm50436107

19. Bms742413

20. Who 11512

21. Hy-134992

22. Cs-0168642

2.4 Create Date
2011-11-07
3 Chemical and Physical Properties
Molecular Weight 638.8 g/mol
Molecular Formula C36H46N8O3
XLogP33.1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass638.36928736 g/mol
Monoisotopic Mass638.36928736 g/mol
Topological Polar Surface Area117 Ų
Heavy Atom Count47
Formal Charge0
Complexity1160
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Moehs Iberica

02

Axplora

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAxplora is your partner of choice for complex APIs.

Flag Germany
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Axplora CB

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

04

HRV Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
TAPI Company Banner

06

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner

07

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

08

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

09

Formosa Laboratories

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Formosa Laboratories

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

10

LAXAI Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

LAXAI Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41470

Submission : 2025-03-11

Status : Active

Type : II

Moehs Iberica

02

Cipla Ltd

India

USDMF

arrow
RDD
Not Confirmed

02

03

RDD
Not Confirmed

04

RDD
Not Confirmed

05

Xuzhou Wanbang Jinqiao Pharma Co Ltd

Country

USDMF

arrow
RDD
Not Confirmed

05

Xuzhou Wanbang Jinqiao Pharma Co Ltd

Country
arrow
RDD
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42616

Submission : 2025-10-31

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Pfizer Inc

U.S.A
RDD
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
RDD
Not Confirmed

ZAVEGEPANT HYDROCHLORIDE

Brand Name : ZAVZPRET

Dosage Form : SPRAY, METERED;NASAL

Dosage Strength : EQ 10MG BASE/SPRAY

Packaging :

Approval Date : 2023-03-09

Application Number : 216386

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

PFIZER

U.S.A
RDD
Not Confirmed
arrow

PFIZER

U.S.A
arrow
RDD
Not Confirmed

ZAVEGEPANT HYDROCHLORIDE

Brand Name : ZAVZPRET

Dosage Form : SPRAY, METERED;NASAL

Dosage Strength : EQ 10MG BASE/SPRAY

Approval Date : 2023-03-09

Application Number : 216386

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1337918-83-8 / Zavegepant HCl API manufacturers, exporters & distributors?

Zavegepant HCl manufacturers, exporters & distributors 1

26

PharmaCompass offers a list of Zavegepant HCl API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Zavegepant HCl manufacturer or Zavegepant HCl supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zavegepant HCl manufacturer or Zavegepant HCl supplier.

API | Excipient name

Zavegepant HCl

Synonyms

Vazegepant, Bms-742413, Bhv-3500, Zavegepant [usan], Odu3zaz94j, Bms-742413-01

Cas Number

1337918-83-8

Unique Ingredient Identifier (UNII)

ODU3ZAZ94J

About Zavegepant HCl

Zavegepant is a highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, with potential analgesic and immunomodulating activities. Upon administration, zavegepant targets, binds to and inhibits the activity of CGRP receptors located on mast cells in the brain. This may inhibit neurogenic inflammation caused by trigeminal nerve release of CGRP. In addition, by blocking the CGRP receptors located in smooth muscle cells within vessel walls, zavegepant inhibits the pathologic dilation of intracranial arteries. Zavegepant, by blocking the CGRP receptors, also suppresses the transmission of pain by inhibiting the central relay of pain signals from the trigeminal nerve to the caudal trigeminal nucleus. Altogether, this may relieve migraine. As CGRP receptors induce the release of pro-inflammatory mediators, such as interleukin-6 (IL-6), from inflammatory cells, zavegepant may prevent an IL-6-mediated inflammatory response. Zavegepant may also inhibit the CGRP-mediated induction of eosinophil migration and the stimulation of beta-integrin-mediated T cell adhesion to fibronectin at the site of inflammation, and may abrogate the CGRP-mediated polarization of the T cell response towards the pro-inflammatory state characterized by Th17 and IL-17. This may improve lung inflammation and oxygenation, prevent edema, and further lung injury. CGRP, a 37 amino-acid peptide expressed in and released from a subset of polymodal primary sensory neurons of the trigeminal ganglion and nerve fibers projecting to the airways and by pulmonary neuroendocrine cells, plays an important role in pain transmission, inflammation, and neurogenic vasodilatation. It is released upon acute lung injury and upregulation of transient receptor potential (TRP) channels.

Zavegepant Manufacturers

A Zavegepant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zavegepant, including repackagers and relabelers. The FDA regulates Zavegepant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zavegepant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Zavegepant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Zavegepant Suppliers

A Zavegepant supplier is an individual or a company that provides Zavegepant active pharmaceutical ingredient (API) or Zavegepant finished formulations upon request. The Zavegepant suppliers may include Zavegepant API manufacturers, exporters, distributors and traders.

click here to find a list of Zavegepant suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Zavegepant USDMF

A Zavegepant DMF (Drug Master File) is a document detailing the whole manufacturing process of Zavegepant active pharmaceutical ingredient (API) in detail. Different forms of Zavegepant DMFs exist exist since differing nations have different regulations, such as Zavegepant USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Zavegepant DMF submitted to regulatory agencies in the US is known as a USDMF. Zavegepant USDMF includes data on Zavegepant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Zavegepant USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Zavegepant suppliers with USDMF on PharmaCompass.

Zavegepant WC

A Zavegepant written confirmation (Zavegepant WC) is an official document issued by a regulatory agency to a Zavegepant manufacturer, verifying that the manufacturing facility of a Zavegepant active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Zavegepant APIs or Zavegepant finished pharmaceutical products to another nation, regulatory agencies frequently require a Zavegepant WC (written confirmation) as part of the regulatory process.

click here to find a list of Zavegepant suppliers with Written Confirmation (WC) on PharmaCompass.

Zavegepant NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zavegepant as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Zavegepant API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Zavegepant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Zavegepant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zavegepant NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Zavegepant suppliers with NDC on PharmaCompass.

Zavegepant GMP

Zavegepant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Zavegepant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Zavegepant GMP manufacturer or Zavegepant GMP API supplier for your needs.

Zavegepant CoA

A Zavegepant CoA (Certificate of Analysis) is a formal document that attests to Zavegepant's compliance with Zavegepant specifications and serves as a tool for batch-level quality control.

Zavegepant CoA mostly includes findings from lab analyses of a specific batch. For each Zavegepant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Zavegepant may be tested according to a variety of international standards, such as European Pharmacopoeia (Zavegepant EP), Zavegepant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zavegepant USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty